Company intelligence / Profile preview

Noselab

Munich, Bavaria, Germanynoselab.com ↗

Ownership: Private
Development stage: Other

Overview

Noselab has developed a proprietary, AI-driven diagnostic platform that analyzes molecular biomarkers in nasal secretions to enable early and accurate diagnosis of neurodegenerative diseases. The company is focused on improving detection and personalized treatment options, with particular emphasis on conditions such as Alzheimer's disease. Clinical results are not publicly detailed, but the technology is positioned as innovative and ground-breaking within its field.

Therapeutic areas: Neurology
Modalities: DeviceDiagnostic platform (AI-based)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Noselab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noselab.

Explore the full profile